Amplia Therapeutics Limited (ATX:ASX)


right-arrow Created with Sketch. 0 (0%)
MCAP $31.23M
Last trade 16.10pm 22/01/2021 20mins delayed

Latest Announcements

11/01/2021ATXAmplia Therapeutics Limited
17/12/2020ATXAmplia Therapeutics Limited
02/12/2020 Price SensitivePSATXAmplia Therapeutics Limited
27/11/2020 Price SensitivePSATXAmplia Therapeutics Limited
24/11/2020ATXAmplia Therapeutics Limited
02/11/2020ATXAmplia Therapeutics Limited
29/10/2020 Price SensitivePSATXAmplia Therapeutics Limited
21/10/2020ATXAmplia Therapeutics Limited

Company Overview

Amplia Therapeutics Limited, formerly Innate Immunotherapeutics Limited, is a pharmaceutical company. The Company is engaged in research and development of immune-oncology drugs and chemotherapies to address serious unmet needs in fibrotic tumors. The Company is focused on advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis, particularly focused on pancreatic and ovarian cancer. Its initial clinical development pipeline comprises of two novel orally available small molecule FAK inhibitors: AMP945 (FAK-only) and AMP886 (FAK/FLT3/VEGFR3).

ATX in the news

Search Previous Announcements